Suchergebnisse - "Tabernero, J"

PubPharm (26)

1

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2023

von Toledano-Fonseca, M. | Gómez-España, M. | Élez, E. | +19

2

MODUL cohort 2 : an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer

enthalten in: ESMO open | 2022

von Tabernero, J. | Grothey, A. | Arnold, D. | +8

3

Management of BRAF-mutant metastatic colorectal cancer : a review of treatment options and evidence-based guidelines

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Grothey, A. | Fakih, M. | Tabernero, J.

4

Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von André, T. | Vernerey, D. | Im, S. | +18

5

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19

6

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

7

DPYD genotype-guided fluoropyrimidines dose : is it ready for prime time?

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Páez, D. | Salazar, R. | Tabernero, J.

CommentOn: Ann Oncol. 2017 Dec 1;28(12 ):2915-2922. - PMID 29045513

8

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Taieb, J. | Balogoun, R. | Le Malicot, K. | +18

9

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

10

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6